RhumbLine Advisers’s Filana Therapeutics FLNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,734
| Closed | -$2.93K | – | 4229 |
|
|
2026
Q1 | $2.93K | Hold |
1,734
| – | – | ﹤0.01% | 3912 |
|
|
2025
Q4 | $3.43K | Hold |
1,734
| – | – | ﹤0.01% | 3946 |
|
|
2025
Q3 | $5.04K | Hold |
1,734
| – | – | ﹤0.01% | 3915 |
|
|
2025
Q2 | $3.14K | Sell |
1,734
-57,224
| -97% | -$102K | ﹤0.01% | 3956 |
|
|
2025
Q1 | $88.4K | Buy |
58,958
+1,129
| +2% | +$2.85K | ﹤0.01% | 3432 |
|
|
2024
Q4 | $136K | Buy |
57,829
+1,672
| +3% | +$29.4K | ﹤0.01% | 3373 |
|
|
2024
Q3 | $1.65M | Sell |
56,157
-3,102
| -5% | -$71.4K | ﹤0.01% | 2007 |
|
|
2024
Q2 | $732K | Buy |
59,259
+2,322
| +4% | +$48.9K | ﹤0.01% | 2420 |
|
|
2024
Q1 | $1.16M | Buy |
56,937
+835
| +1% | +$19.2K | ﹤0.01% | 2175 |
|
|
2023
Q4 | $1.26M | Sell |
56,102
-647
| -1% | -$13.7K | ﹤0.01% | 2141 |
|
|
2023
Q3 | $944K | Sell |
56,749
-252
| -0.4% | -$4.99K | ﹤0.01% | 2244 |
|
|
2023
Q2 | $1.4M | Buy |
57,001
+4,448
| +8% | +$107K | ﹤0.01% | 2115 |
|
|
2023
Q1 | $1.27M | Buy |
52,553
+781
| +2% | +$21.6K | ﹤0.01% | 2023 |
|
|
2022
Q4 | $1.53M | Buy |
51,772
+365
| +0.7% | +$13.1K | ﹤0.01% | 1926 |
|
|
2022
Q3 | $2.15M | Buy |
51,407
+4,625
| +10% | +$125K | ﹤0.01% | 1717 |
|
|
2022
Q2 | $1.32M | Buy |
46,782
+5,638
| +14% | +$142K | ﹤0.01% | 1998 |
|
|
2022
Q1 | $1.53M | Buy |
41,144
+2,230
| +6% | +$94.5K | ﹤0.01% | 1939 |
|
|
2021
Q4 | $1.7M | Sell |
38,914
-1,531
| -4% | -$80.3K | ﹤0.01% | 1968 |
|
|
2021
Q3 | $2.51M | Buy |
40,445
+643
| +2% | +$53.7K | ﹤0.01% | 1768 |
|
|
2021
Q2 | $3.4M | Sell |
39,802
-5,636
| -12% | -$302K | ﹤0.01% | 1651 |
|
|
2021
Q1 | $2.04M | Buy |
45,438
+11,448
| +34% | +$450K | ﹤0.01% | 1900 |
|
|
2020
Q4 | $232K | Buy |
33,990
+11,044
| +48% | +$98.6K | ﹤0.01% | 2773 |
|
|
2020
Q3 | $264K | Buy |
22,946
+923
| +4% | +$4.16K | ﹤0.01% | 2570 |
|
|
2020
Q2 | $68K | Buy |
+22,023
| New | +$99.9K | ﹤0.01% | 3009 |
|
|
2015
Q2 | – | Sell |
-4,689
| Closed | -$62K | – | 3081 |
|
|
2015
Q1 | $62K | Buy |
4,689
+14
| +0.3% | +$189 | ﹤0.01% | 2989 |
|
|
2014
Q4 | $66K | Buy |
4,675
+132
| +3% | +$2.29K | ﹤0.01% | 2988 |
|
|
2014
Q3 | $124K | Hold |
4,543
| – | – | ﹤0.01% | 2900 |
|
|
2014
Q2 | $183K | Buy |
+4,543
| New | +$168K | ﹤0.01% | 2864 |
|
Other funds holding FLNA
GC
RhumbLine Advisers's FLNA Position: Q2 2026 in Review
RhumbLine Advisers sold out of Filana Therapeutics (FLNA) in Q2 2026, closing a stake of 1,734 shares — an estimated $2.93K sold.
RhumbLine Advisers first reported a position in FLNA in Q2 2014 and held it in 28 quarters. The position peaked at $3.4M in Q2 2021. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.
- RhumbLine Advisers reported no remaining Filana Therapeutics position as of Q2 2026 after selling out during the quarter.
- RhumbLine Advisers sold 1,734 Filana Therapeutics shares in Q2 2026, an estimated $2.93K.
- RhumbLine Advisers first reported a position in Filana Therapeutics in Q2 2014 and held it in 28 quarters.
- RhumbLine Advisers's Filana Therapeutics position peaked at $3.4M in Q2 2021.
- 85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.